Literature DB >> 36267716

The pattern of brain metabolism in chronic steno-occlusive cerebral artery disease.

Lingyan Meng1, Zhaodi Huang2, Hui Li2.   

Abstract

Background: Dispersion of gray matter and white matter and abnormal hemodynamic changes are common in patients with chronic stenosis cerebral artery disease. It is not easy to capture these abnormal changes with conventional magnetic resonance imaging (MRI). Magnetic resonance spectroscopy (MRS) is useful for obtaining metabolic information in either preclinical or clinical applications. The aim of our study was to apply MRS to non-invasively investigate changes in brain metabolism in MRI-negative patients with chronic cerebral artery steno-occlusive disease.
Methods: We performed MRS examinations with 3.0T MRI on 34 patients with severe unilateral middle cerebral artery (MCA) stenosis or occlusion without parenchymal abnormalities. Additionally, N-acetylaspartic acid (NAA), creatine (Cr), choline (Cho), NAA/Cr, and Cho/Cr in the coronal, parenchymal, and thalamic regions of the affected brain and contralateral brain were determined. The mean concentrations of NAA, Cr, Cho, NAA/Cr, and Cho/Cr in the coronal, parenchymal, and thalamic regions of the ipsilateral and contralateral brains were compared using the 2-tailed paired t-test.
Results: At the ipsilateral corona radiata and lenticular nucleus, the mean NAA was significantly lower, whereas the Cho and Cho/Cr were significantly higher than the contralateral corona radiata and lentiform nucleus (P<0.05). In addition, the creatine and NAA/Cr values in the coronal region of the affected side were significantly lower than those in the opposite side (P<0.05), but there was no significant difference between the pectin nuclei on both sides. No metabolic changes were found at the ipsilateral thalamus. Conclusions: In this study, we demonstrated that MRS could reveal metabolic changes and that the NAA, NAA/Cr, Cho, and Cho/Cr concentration might be used as indexes for evaluating neuronal damage in the chronic steno-occlusive cerebral artery disease, treatment strategies, and treatment effectiveness. 2022 Annals of Translational Medicine. All rights reserved.

Entities:  

Keywords:  Cerebral arterial steno-occlusive disease; magnetic resonance imaging (MRI); magnetic resonance spectroscopy (MRS)

Year:  2022        PMID: 36267716      PMCID: PMC9577772          DOI: 10.21037/atm-22-3993

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  27 in total

Review 1.  Neurospectroscopy: the past, present and future.

Authors:  Carolyn E Mountford; Peter Stanwell; Alexander Lin; Saadallah Ramadan; Brian Ross
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

2.  Detecting misery perfusion in unilateral steno-occlusive disease of the internal carotid artery or middle cerebral artery by MR imaging.

Authors:  S Xie; L H Hui; J X Xiao; X D Zhang; Q Peng
Journal:  AJNR Am J Neuroradiol       Date:  2011-06-23       Impact factor: 3.825

3.  Microsurgical anatomy of the middle cerebral artery.

Authors:  H Gibo; C C Carver; A L Rhoton; C Lenkey; R J Mitchell
Journal:  J Neurosurg       Date:  1981-02       Impact factor: 5.115

4.  High b-value diffusion tensor imaging of the remote white matter and white matter of obstructive unilateral cerebral arterial regions.

Authors:  X Meng; C Jun; Q Wang; X Zhang; Z Li; Q Li; J Hou; Q Zeng; Q Wang; X Ma
Journal:  Clin Radiol       Date:  2013-04-24       Impact factor: 2.350

5.  Evaluation of brain metabolism in steno-occlusive carotid artery disease by proton MR spectroscopy: a correlative study with oxygen metabolism by PET.

Authors:  C Tsuchida; H Kimura; N Sadato; T Tsuchida; Y Tokuriki; Y Yonekura
Journal:  J Nucl Med       Date:  2000-08       Impact factor: 10.057

6.  Optimal timing for measuring cerebral blood flow after acetazolamide administration to detect preexisting cerebral hemodynamics and metabolism in patients with bilateral major cerebral artery steno-occlusive diseases: 15O positron emission tomography studies.

Authors:  Masakazu Kobayashi; Suguru Igarashi; Tatsuhiko Takahashi; Shunrou Fujiwara; Kohei Chida; Kazunori Terasaki; Yoshitaka Kubo; Kuniaki Ogasawara
Journal:  Am J Nucl Med Mol Imaging       Date:  2021-12-15

Review 7.  N-acetylaspartate: a literature review of animal research on brain ischaemia.

Authors:  Céline Demougeot; Christine Marie; Maurice Giroud; Alain Beley
Journal:  J Neurochem       Date:  2004-08       Impact factor: 5.372

8.  Early time course of N-acetylaspartate, creatine and phosphocreatine, and compounds containing choline in the brain after acute stroke. A proton magnetic resonance spectroscopy study.

Authors:  P Gideon; O Henriksen; B Sperling; P Christiansen; T S Olsen; H S Jørgensen; P Arlien-Søborg
Journal:  Stroke       Date:  1992-11       Impact factor: 7.914

Review 9.  Basic principles and concepts underlying recent advances in magnetic resonance imaging of the developing brain.

Authors:  Ashok Panigrahy; Matthew Borzage; Stefan Blüml
Journal:  Semin Perinatol       Date:  2010-02       Impact factor: 3.300

Review 10.  Clinical proton MR spectroscopy in central nervous system disorders.

Authors:  Gülin Oz; Jeffry R Alger; Peter B Barker; Robert Bartha; Alberto Bizzi; Chris Boesch; Patrick J Bolan; Kevin M Brindle; Cristina Cudalbu; Alp Dinçer; Ulrike Dydak; Uzay E Emir; Jens Frahm; Ramón Gilberto González; Stephan Gruber; Rolf Gruetter; Rakesh K Gupta; Arend Heerschap; Anke Henning; Hoby P Hetherington; Franklyn A Howe; Petra S Hüppi; Ralph E Hurd; Kantarci Kantarci; Dennis W J Klomp; Roland Kreis; Marijn J Kruiskamp; Martin O Leach; Alexander P Lin; Peter R Luijten; Malgorzata Marjańska; Andrew A Maudsley; Dieter J Meyerhoff; Carolyn E Mountford; Sarah J Nelson; M Necmettin Pamir; Jullie W Pan; Andrew C Peet; Harish Poptani; Stefan Posse; Petra J W Pouwels; Eva-Maria Ratai; Brian D Ross; Tom W Scheenen; Christian Schuster; Ian C P Smith; Brian J Soher; Ivan Tkáč; Daniel B Vigneron; Risto A Kauppinen
Journal:  Radiology       Date:  2014-03       Impact factor: 11.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.